Our 2014 approach to mucormycosis

Mycoses

Volumn 57, Issue 9, 2014, Pages 519-524

  Tacke, Daniela ^a   Koehler, Philipp ^a,b   Markiefka, Birgid ^a   Cornely, Oliver A ^a,b,c,d  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Immunocompromised host; Invasive fungal infection; Liposomal amphotericin B; Posaconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ISAVUCONAZOLE; POSACONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

CLINICAL FEATURE; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; FUNGUS CULTURE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPROMISED PATIENT; MICROSCOPY; MUCORALES; MUCORMYCOSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ISOLATION AND PURIFICATION;

FUNGI; MUCORALES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DEBRIDEMENT; HUMANS; IMMUNOCOMPROMISED HOST; MUCORALES; MUCORMYCOSIS; TRIAZOLES;

EID: 84905721827     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12203     Document Type: Review

References (47)

1. Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 2012; 54(Suppl. 1): S8-S15.
2. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54(Suppl. 1): S23-S34.
3. Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859-67.
4. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
5. Rammaert B, Lanternier F, Poiree S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. Diabetes Metab 2012; 38: 193-204.
6. Antoniadou A. Outbreaks of zygomycosis in hospitals. Clin Microbiol Infect 2009; 15(Suppl. 5): 55-59.
7. Neblett Fanfair R, Benedict K, Bos J et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med 2012; 367: 2214-25.
8. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47: 503-9.
9. Kontoyiannis DP, Azie N, Franks B, Horn DL. Prospective antifungal therapy (PATH) alliance: focus on mucormycosis. Mycoses 2014; 57: 240-6.
10. Meis JF, Kullberg BJ, Pruszczynski M, Veth RP. Severe osteomyelitis due to the zygomycete Apophysomyces elegans. J Clin Microbiol 1994; 32: 3078-81.
11. Koehler P, Tacke D, Cornely OA. Aspergillosis of bones and joints - a review from 2002 until today. Mycoses 2014; doi: 10.1111/myc.12165. [Epub ahead of print].
12. Mehta NN, Romanelli J, Sutton MG. Native aortic valve vegetative endocarditis with Cunninghamella. Eur J Echocardiogr 2004; 5: 156-8.
13. Sanchez-Recalde A, Merino JL, Dominguez F, Mate I, Larrea JL, Sobrino JA. Successful treatment of prosthetic aortic valve mucormycosis. Chest 1999; 116: 1818-20.
14. Lewis RE, Cahyame-Zuniga L, Leventakos K et al. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 2013; 56: 638-45.
15. Lanternier F, Dannaoui E, Morizot G et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis 2012; 54(Suppl. 1): S35-S43.
16. Mohindra S, Mohindra S, Gupta R, Bakshi J, Gupta SK. Rhinocerebral mucormycosis: the disease spectrum in 27 patients. Mycoses 2007; 50: 290-6.
17. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41: 60-66.
18. Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 2008; 46: 1733-7.
19. Legouge C, Caillot D, Chretien ML et al. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis 2014; 58: 672-8.
20. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012; 54(Suppl. 1): S55-S60.
21. Herrera DA, Dublin AB, Ormsby EL, Aminpour S, Howell LP. Imaging findings of rhinocerebral mucormycosis. Skull Base 2009; 19: 117-25.
22. Koc Z, Koc F, Yerdelen D, Ozdogu H. Rhino-orbital-cerebral mucormycosis with different cerebral involvements: infarct, hemorrhage, and ophthalmoplegia. Int J Neurosci 2007; 117: 1677-90.
23. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011; 52: 1144-55.
24. Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001; 125: 375-8.
25. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13: 236-301.
26. Cornely OA, Arikan-Akdagli S, Dannaoui E et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20(Suppl. 3): 5-26. doi:10.1111/1469-0691.12371.
27. Khan ZU, Ahmad S, Brazda A, Chandy R. Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole. J Clin Microbiol 2009; 47: 1244-8.
28. Alastruey-Izquierdo A, Castelli MV, Cuesta I, Monzon A, Cuenca-Estrella M, Rodriguez-Tudela JL. Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob Agents Chemother 2009; 53: 1686-9.
29. Vitale RG, de Hoog GS, Schwarz P et al. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. J Clin Microbiol 2012; 50: 66-75.
30. Dannaoui E, Meis JF, Mouton JW, Verweij PE. In vitro susceptibilities of Zygomycota to polyenes. J Antimicrob Chemother 2002; 49: 741-4.
31. Alvarez E, Garcia-Hermoso D, Sutton DA et al. Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus Saksenaea. J Clin Microbiol 2010; 48: 4410-6.
32. Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57: 1044-50.
33. Valentini CG, Candoni A, Fianchi L et al. Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies. Mycoses 2010; 53: 89-92.
34. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 207-14.
35. Ruping MJ, Heinz WJ, Kindo AJ et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65: 296-302.
36. Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 2010; 54: 1298-304.
37. Lanternier F, Poiree S, Elie C et al. Pilot prospective study of high dose (10 mg/kg/d) liposomal amphotericin B for the initial treatment of mucormycosis: "AMBIZYGO" Trial (M-1707). 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 2012.
38. Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood 2011; 118: 1216-24.
39. Reed C, Bryant R, Ibrahim AS et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47: 364-71.
40. Greenberg RN, Mullane K, van Burik JA et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-33.
41. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-e65.
42. Vehreschild JJ, Birtel A, Vehreschild MJ et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013; 39: 310-24.
43. Pagano L, Cornely OA, Busca A et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica 2013; 98: e127-30.
44. Spellberg B, Fu Y, Edwards JE, Jr, Ibrahim AS. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 2005; 49: 830-2.
45. Guembe M, Guinea J, Pelaez T, Torres-Narbona M, Bouza E. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob Agents Chemother 2007; 51: 3457-8.
46. Perkhofer S, Locher M, Cuenca-Estrella M et al. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob Agents Chemother 2008; 52: 2636-8.
47. Luo G, Gebremariam T, Lee H, Edwards JE, Jr, Kovanda L, Ibrahim AS. Isavuconazole therapy protects immunosuppressed mice from mucormycosis. Antimicrob Agents Chemother 2014; 58: 2450-3.